84 related articles for article (PubMed ID: 22421369)
1. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ
Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369
[TBL] [Abstract][Full Text] [Related]
2. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM
Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
[TBL] [Abstract][Full Text] [Related]
4. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
[TBL] [Abstract][Full Text] [Related]
5. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.
Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ
J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
[TBL] [Abstract][Full Text] [Related]
7. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.
Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ
J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358
[TBL] [Abstract][Full Text] [Related]
8. ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model.
Heravi M; Kumala S; Rachid Z; Jean-Claude BJ; Radzioch D; Muanza TM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):399-406. PubMed ID: 25823448
[TBL] [Abstract][Full Text] [Related]
9. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Matheson SL; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.
Banerjee R; Rachid Z; McNamee J; Jean-Claude BJ
J Med Chem; 2003 Dec; 46(25):5546-51. PubMed ID: 14640561
[TBL] [Abstract][Full Text] [Related]
11. The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.
Banerjee R; Huang Y; Qiu Q; McNamee JP; Belinsky G; Jean-Claude BJ
Cell Signal; 2011 Apr; 23(4):630-40. PubMed ID: 21138763
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status.
Rachid Z; Brahimi F; Domarkas J; Jean-Claude BJ
Bioorg Med Chem Lett; 2005 Feb; 15(4):1135-8. PubMed ID: 15686928
[TBL] [Abstract][Full Text] [Related]
13. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA.
Brahimi F; Rachid Z; Qiu Q; McNamee JP; Li YJ; Tari AM; Jean-Claude BJ
Int J Cancer; 2004 Nov; 112(3):484-91. PubMed ID: 15382076
[TBL] [Abstract][Full Text] [Related]
14. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.
Todorova MI; Larroque AL; Dauphin-Pierre S; Fang YQ; Jean-Claude BJ
Mol Cancer Ther; 2010 Apr; 9(4):869-82. PubMed ID: 20354119
[TBL] [Abstract][Full Text] [Related]
15. A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity.
Golabi N; Brahimi F; Huang Y; Rachid Z; Qiu Q; Larroque-Lombard AL; Jean-Claude BJ
J Pharm Biomed Anal; 2011 Nov; 56(3):592-9. PubMed ID: 21764236
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK.
Larroque-Lombard AL; Todorova M; Qiyu Q; Jean-Claude B
Chem Biol Drug Des; 2011 May; 77(5):309-18. PubMed ID: 21294849
[TBL] [Abstract][Full Text] [Related]
17. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.
Qiu Q; Dudouit F; Matheson SL; Brahimi F; Banerjee R; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):1-10. PubMed ID: 12497200
[TBL] [Abstract][Full Text] [Related]
18. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
19. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.
Matheson SL; Brahimi F; Jean-Claude BJ
Biochem Pharmacol; 2004 Mar; 67(6):1131-8. PubMed ID: 15006549
[TBL] [Abstract][Full Text] [Related]
20. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.
Qiu Q; Domarkas J; Banerjee R; Merayo N; Brahimi F; McNamee JP; Gibbs BF; Jean-Claude BJ
Clin Cancer Res; 2007 Jan; 13(1):331-40. PubMed ID: 17200372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
